4. Ministry of Food and Drug Safety. MFDS completed investigating all the valsartans (raw material for antihypertensive drug) 23/08/2018 [Internet] Cheongju: Ministry of Food and Drug Safety. 2018;cited 2019 Mar 1. Available from:
http://www.mfds.go.kr/brd/m_99/view.do?seq=42992
5. Ministry of Food and Drug Safety. MFDS distributed a guideline for managing sartan's impurity 21/11/2018 [Internet] Cheongju: Ministry of Food and Drug Safety. 2018;cited 2019 Mar 1. Available from:
http://www.mfds.go.kr/brd/m_99/view.do?seq=43128
6. Ministry of Food and Drug Safety. MFDS reported the results of evaluating the clinical outcome of patients taking valsartan (raw material for antihypertensive drug) and further investigation19/12/2018 [Internet] Cheongju: Ministry of Food and Drug Safety. 2018;cited 2019 Mar 1. Available from:
http://www.mfds.go.kr/brd/m_99/view.do?seq=43167
7. Ministry of Food and Drug Safety. Korea became a regular member of ICH, which proved Korea to be an advanced country in drug regulation14/11/2016 [Internet] Cheongju: Ministry of Food and Drug Safety. cited 2019 Mar 1. Available from:
http://www.mfds.go.kr/brd/m_99/view.do?seq=34354
8. Park BJ. Role of pharmaceutical companies in pharmacoepidemiology and risk management. In: Park BJ, editor. Pharmacoepidemiology. Seoul: Seoul National University Press; 2011. p. 49-58.
9. Park BJ. Role of clinicians in pharmacoepidemiology and risk management. In: Park BJ, editor. Pharmacoepidemiology. Seoul: Seoul National University Press; 2011. p. 30-39.
10. Park BJ. Cohort study. In: Park BJ, editor. Pharmacoepidemiology. Seoul: Seoul National University Press; 2011. p. 192-203.
11. Park BJ. Role of government in pharmacoepidemiology and risk management. In: Park BJ, editor. Pharmacoepidemiology. Seoul: Seoul National University Press; 2011. p. 59-71.